Recent advances in personalised regenerative medicine have been significant. However, further developments are needed to support market and regulatory demands, particularly the development of manufacturing processes to support large scale batches of high-quality viral vectors.
Pall Corporation provides specialist bioprocessing and manufacturing solutions to global researchers, developers, and manufacturers of large and small molecule drugs.
Pall Biotech works closely with drug manufacturers for a wide range of services including research and development (R&D), fill / finish operations, and commercial production.
The company works to consistently improve its portfolio of traditional and single-use products to help maintain global health and advance patient safety.
Dedicated drug manufacturing and scientific laboratories
Pall Corporation has a global network of ISO 9001 certified manufacturing facilities, which are used to develop and produce pharmaceuticals through traditional and single-use upstream, downstream, and viral filtration technologies.
These state-of-the-art scientific and laboratory service (SLS) facilities are located worldwide and provide compatibility studies, extractable and leachable studies, particular validation, and analytical biopharmaceutical testing.
The laboratories facilitate a wide range of scalable, integrated solutions to researchers worldwide for the manufacture of biopharmaceuticals, cell and gene therapies, vaccines and plasma, and active pharmaceutical ingredients (API). Available product types available include capsules, bioreactors, cartridges, membranes, sterile connectors, and syringe filters.
Optimisation of downstream bioprocessing
Pall Biotech focuses on semi and fully continuous bioprocessing solutions and launches commercially viable offerings for clients working with small or large molecules.
The Cadence portfolio includes the Cadence Inline Concentrator (ILC), Cadence BioSMB PD System, Cadence BioSMB Process 350 System, and the Cadance Acoustic Separator (CAS) technologies. These support downstream processes for optimised production of highly shear-sensitive products, increase capacity, and reduce costs.
ILC simplifies the implementation of single-pass tangential flow filtration (TFF) in applications involving biotechnology, vaccine formation, and blood plasma. The new technology can be installed into a process system or operated as a standalone unit. It couples the concentration of product before or after other downstream processing steps to optimise manufacture and reduce in-process pool tank volumes.
The Cadence BioSMB PD System is a multi-column chromatography solution that is fully scalable from process development facilities to good manufacturing practices (GMP) manufacturing. It can reduce costs of chromatographic media by up to 80%, increasing efficiency and productivity.
The Cadance BioSMB Process 350 System is a multicolumn chromatography system that can be adapted to a wide number of applications. High-throughput and efficient media utilisation is achieved through a single-use, eight-column structure that allows flexible flow configuration through a single-use valve cassette. This technology is scalable to commercial manufacture.
The Cadence Acoustic Separator is used to remove Chinese hamster ovary (CHO) cells and debris using a single-use chamber to clarify harvested cell culture fluid (HCCF) ready for downstream processing, which is optimised to provide an alternative to centrifugation.
Technical support for automation and streamlining bioprocesses
The Pall Advanced Separation Systems (PASS) facilities provide customers with the necessary support and technical capabilities required to automate production, scale-up operations, and streamline bioprocesses.
Pall’s team validates manufacturing processes and offers technical support, including assurance of global regulatory compliance.
About Pall Corporation
Based in Port Washington, New York, Pall Corporation was founded in 1946 as a high-tech filtration, separation, and purification company in the airline industry. Over the last 70 years, the company has grown and divided into industrial and life sciences business segments.
Pall Biotech supports drug and vaccine developers with solutions such as upstream cell culture technologies, chromatography platforms, depth filtration, flexible filling, and manufacturing.
Founded by Dr David B Pall in 1946, Pall Corporation has grown from a company producing filters for the airline industry to a global innovator in high-tech filtration, separation and purification across many markets.
Selecting the right filter integrity test instrument is an important task. An informed, balanced choice will support seamless integration of the instrument into critical processes and provide trouble-free operation for years to come.
Pall Biotech has announced a new end-to-end integrated platform solution that accelerates development, reduces risk and simplifies your process for gene therapy manufacturing.
Pall Corporation has established a Biotech Integrated Solutions Center of Excellence (CoE) in Shanghai, China.
Pall Corporation has won a £1.5m shared grant from Innovate UK to investigate continuous manufacturing for gene therapies, in partnership with Cobra Biologics and Gene Therapy Catapult.
Prefabricated and prequalified cleanroom solutions provider G-CON Manufacturing is collaborating with Pall Corporation to bring turnkey continuous bioprocess or viral vector production facility solutions to the industry.
Pall Corporation has formed a strategic partnership with experienced cell line and expression technology platform development company Celltheon Corporation.
Pall Corporation has partnered with Pall Biotech to launch a new training course focused on industry advances.
Pall Biotech has announced it is participating in a webinar titled ‘Finding the Common Road to Quality for Single-Use Materials’.
Pall Corporation has announced a strategic collaboration between its Biotech business unit and Artesyn Biosolutions, a leading innovator in single-use components and fluid management technologies.
Pall Corporation has been recognised as a downstream innovator for the Cadence BioSMB Process system from Pall Biotech.
Pall Corporation has announced the opening of its expanded Hoegaarden office after eight months of construction.
The Stax mAx clarification platform is a single-use, robust depth filtration solution for the economic clarification of monoclonal antibody cell cultures without the need for centrifugation or process additives.